Tuesday, September 30, 2014

Nanomedicine – taking excellence to the market

Since its inception, the European Technology Platform on Nanomedicine (ETPN) has defined its role as providing an industrial perspective on the application of nanotechnology to human healthcare. Whilst societal need has been the primary driver for healthcare projects, it will not be sufficient without a genuine and integrated supply chain in Europe. Indeed, there is a strong need to align academia and SMEs to the real and challenging development steps and requirements associated with the industrialisation of innovative medicines. This can only happen if the system is deeply redesigned to support academic and industrial stakeholders along their translation process from ideas and then technologies into medical products. It is of the utmost importance that applied topics are supplied by stakeholders serving end users – and the markets – and peer-reviewed by a panel taking industrial interests into consideration in order to successfully introduce nanomedical products, issued from excellent research conducted in Europe during the last decade, to the market.
By definition, nanomedicine is a cross-enabling technologies approach, translating cutting-edge research in physics, chemistry, optics, fluidics, electronics, and many other fields into innovative medical solutions for better and more efficient diagnosis, imaging and therapies

Click for complete report
Subscribe to NBIC News